Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pancolitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Pancolitis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-002782-32 Sponsor Protocol Number: C13006 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative C...
    Medical condition: Moderate to Severe Ulcerative Colitis Colitis ulcerosa moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) DK (Completed) IS (Completed) PT (Prematurely Ended) BE (Completed) FR (Completed) GB (Completed) BG (Completed) IT (Completed) MT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003490-10 Sponsor Protocol Number: GETAID-2018-01 Start Date*: 2019-09-30
    Sponsor Name:GETAID
    Full Title: An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with ulcerative cOlitis initiating adalimumab : The CONTROL tr...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003228-54 Sponsor Protocol Number: PBF-677-3 Start Date*: 2018-05-28
    Sponsor Name:PaloBiofarma S.L.
    Full Title: A Phase IIa (proof of concept), randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety and efficacy of oral treatment with PBF-677 in patients with mild to ...
    Medical condition: Inflammatory Bowel disease, mild to moderate Ulcerative Colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000891-13 Sponsor Protocol Number: STW5-II/212-D-12-II-F;IMP17155 Start Date*: 2014-07-21
    Sponsor Name:Steigerwald Arzneimittelwerk GmbH
    Full Title: A randomised, double-blind, placebo-controlled multi-centre study to investigate the effectiveness and safety of STW5-II as add-on treatment for induction of remission in patients with mild to mode...
    Medical condition: Ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002537-41 Sponsor Protocol Number: 20170104 Start Date*: 2022-01-06
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Sev...
    Medical condition: Moderate to Severe Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) DK (Ongoing) NL (Ongoing) DE (Ongoing) HU (Ongoing) FI (Ongoing) BG (Ongoing) IT (Ongoing) GR (Ongoing) ES (Ongoing) BE (Ongoing) RO (Ongoing) SK (Ongoing) LV (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000482-31 Sponsor Protocol Number: MLN0002SC-3030 Start Date*: 2016-01-22
    Sponsor Name:Takeda Development Centre Europe, Ltd.
    Full Title: A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn’s Disease
    Medical condition: Ulcerative Colitis Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) NL (Ongoing) BG (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) SE (Completed) DK (Completed) LT (Completed) ES (Prematurely Ended) HU (Completed) RO (Ongoing) HR (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002783-33 Sponsor Protocol Number: C13007 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Dise...
    Medical condition: Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) SK (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) MT (Completed) GB (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000481-58 Sponsor Protocol Number: MLN0002SC-3031 Start Date*: 2016-01-22
    Sponsor Name:Takeda Development Centre Europe, Ltd.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Cr...
    Medical condition: Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) NL (Completed) BG (Completed) GB (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) LT (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002030-37 Sponsor Protocol Number: A7281009 Start Date*: 2013-01-08
    Sponsor Name:Pfizer Inc.
    Full Title: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS ...
    Medical condition: Crohn’s Disease (CD) and Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) IT (Completed) PL (Completed) SK (Completed) HU (Completed) CZ (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001942-28 Sponsor Protocol Number: APD334-003 Start Date*: 2015-12-10
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerativ...
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) ES (Completed) DE (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) PL (Completed) BG (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003708-29 Sponsor Protocol Number: B7981005 Start Date*: 2017-04-18
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe...
    Medical condition: Moderate to severe Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) DK (Completed) DE (Completed) AT (Completed) PL (Completed) HU (Completed) ES (Completed) NL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003986-33 Sponsor Protocol Number: APD334-302 Start Date*: 2019-07-01
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) FR (Completed) DK (Completed) LT (Completed) BG (Completed) PT (Completed) LV (Prematurely Ended) HU (Completed) PL (Completed) HR (Completed) ES (Ongoing) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-003169-19 Sponsor Protocol Number: CYC-201 Start Date*: 2009-11-09
    Sponsor Name:Sigmoid Pharma Ltd
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004230-28 Sponsor Protocol Number: 1368-0005 Start Date*: 2018-02-27
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely ...
    Medical condition: Moderate-to-severely active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Prematurely Ended) DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004300-34 Sponsor Protocol Number: MLN0002-3024 Start Date*: 2021-06-25
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative C...
    Medical condition: Moderately to severely active Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Ongoing) SK (Prematurely Ended) HU (Ongoing) GR (Ongoing) IT (Ongoing) ES (Prematurely Ended) HR (Ongoing) BE (Ongoing) Outside EU/EEA PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002673-21 Sponsor Protocol Number: 35RC17_8841_EFFICACI Start Date*: 2018-09-04
    Sponsor Name:Centre Hospitalier Universitaire de Rennes
    Full Title: EFFICACI : EFFicacy of intravenous Infliximab versus vedolizumab after failure of subCutaneous Anti-TNF in patients with UlCerative colitis : A double blinded Randomized Clinical Trial.
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004090-50 Sponsor Protocol Number: CT-OST-122-02 Start Date*: 2020-02-07
    Sponsor Name:ONCOSTELLAE S.L.
    Full Title: A Phase Ib/IIa, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with modera...
    Medical condition: Moderate to severe ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003999-39 Sponsor Protocol Number: C2501003 Start Date*: 2020-08-17
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVER...
    Medical condition: moderate to severe ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000152-96 Sponsor Protocol Number: 2016-01 Start Date*: 2019-12-16
    Sponsor Name:GETAID
    Full Title: Intensive Treatment to Reach the target with Golimumab in ulcErative coliTis – In-TARGET
    Medical condition: Moderate to severe ulcerative colitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003050-23 Sponsor Protocol Number: VTX002-201 Start Date*: 2021-10-25
    Sponsor Name:Oppilan Pharma Ltd., wholy owned subsidiary of Ventyx Biosciences Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcer...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) PL (Ongoing) HU (Ongoing) LT (Ongoing) IT (Ongoing) BG (Ongoing) SK (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA